Outcome of the Board Meeting
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences reported significantly widened losses for FY26 with standalone net loss of Rs. 5,486.28 lakhs (vs Rs. 4,707.98 lakhs in FY25) and consolidated net loss of Rs. 27,634.41 lakhs (vs Rs. 16,074.50 lakhs). Q4 standalone loss was Rs. 1,116.73 lakhs on total income of Rs. 829.79 lakhs. The company's wholly-owned US subsidiary Suven Neurosciences Inc contributed Rs. 22,148.12 lakhs to consolidated losses. R&D expenses remain substantial at Rs. 2,797.24 lakhs (standalone) and Rs. 24,818.81 lakhs (consolidated). The Board approved preferential warrant conversion with Rs. 75,715.41 lakhs received and Rs. 50,363.89 lakhs utilized. BSE waived regulatory fines for prior period non-compliance while NSE waiver outcome is pending.
The stock may face negative sentiment due to significantly higher losses and uncertainty around profitability timeline. The substantial R&D spending indicates ongoing investment in drug development but with no near-term revenue visibility. Regulatory compliance issues noted.